Closed-loop MPC-based artificial pancreas: Handling circadian variability of insulin sensitivity

2020 ◽  
Author(s):  
Pablo Abuin ◽  
Juan E. Sereno ◽  
Antonio Ferramosca ◽  
Alejandro H. Gonzalez
Keyword(s):  
Insulin Sensitivity ◽  
Closed Loop ◽  
Artificial Pancreas

1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1054-P
Author(s):  
MICHELE SCHIAVON ◽  
ALFONSO GALDERISI ◽  
KRISTEN A. KRAEMER ◽  
CLAUDIO COBELLI ◽  
CHIARA DALLA MAN ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Sensitivity ◽  
Closed Loop

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

2021 ◽  
Author(s):  
Coralie Amadou ◽  
Sylvia Franc ◽  
Pierre-Yves Benhamou ◽  
Sandrine Lablanche ◽  
Erik Huneker ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Adverse Events ◽  
Closed Loop ◽  
Artificial Pancreas ◽  
Real Life ◽  
Serious Adverse Events ◽  
Life Conditions ◽  
Time In Range

<b>OBJECTIVE </b> <p>To analyze safety and efficacy of the DBLG1 hybrid closed-loop artificial pancreas system in patients with Type 1 Diabetes in real life conditions. </p> <p> </p> <p><b>METHODS</b></p> <p>Following a one-week run-in period with usual pump, 25 patients were provided with the commercial DBLG1 system. We present the results of Time-in-Range and HbA1c over a 6-month period.</p> <p><b> </b></p> <p><b>RESULTS</b></p> <p>The mean (SD;range) age of patients was 43 years (13.8; 25-72). At baseline, mean HbA1c and TIR 70-180mg/dL were respectively 7.9% (0.93; 5.6- 8.5) [63mmol/mol (10; 38-69)] and 53% (16.4;21-85). One patient stopped using the system after 2 months. At 6-month, mean HbA1c decreased to 7.1% [54mmol/mol] (p<0.001) and TIR 70-180mg/dL increased to 69.7% (p<0.0001). TIR<70mg/dL decreased from 2.4 to 1.3% (p=0.03). TIR<54mg/dL decreased from 0.32 to 0.24% (p=0.42). No serious adverse event was reported during the study. </p> <p> </p> <p><b>CONCLUSION</b></p> <p>The DBLG1 System confirms its ability to significantly improve glycemic control in real life conditions, without serious adverse events. </p>

Hardware and Software Implementation of an Artificial Pancreas System on a Mobile Device

2017 ◽  
Vol 8 (1) ◽  
pp. 14-28
Author(s):  
Caterina Lazaro ◽  
Erdal Oruklu ◽  
Mert Sevil ◽  
Kamuran Turksoy ◽  
Ali Cinar
Keyword(s):  
Data Storage ◽  
Mobile Device ◽  
Closed Loop ◽  
Insulin Pump ◽  
Artificial Pancreas ◽  
Vital Signs ◽  
Application Development ◽  
Loop Control ◽  
Remote Server ◽  
Fusion Data

In this work, an artificial pancreas (AP) system, implemented on a mobile device is described. The proposed AP platform integrates hardware (insulin pump, glucose monitor, various sensors for vital signs and physical activities) and software (closed-loop control algorithm, sensor fusion, data storage and remote server access) components via smartphone that is running a dedicated Operating System designed for AP systems. Interfacing with this OS and custom application development steps are presented. Closed loop operation is demonstrated with case studies.

Sign in / Sign up

Export Citation Format

Share Document